Publication:
Eliciting the mitochondrial unfolded protein response via NAD(+) repletion reverses fatty liver disease

cris.virtualsource.author-orcid76b02e57-f663-476b-9ad6-0f2ac3c545e8
datacite.rightsopen.access
dc.contributor.authorGariani, Karim
dc.contributor.authorMenzies, Keir J
dc.contributor.authorRyu, Dongryeol
dc.contributor.authorWegner, Casey J
dc.contributor.authorWang, Xu
dc.contributor.authorRopelle, Eduardo R
dc.contributor.authorMoullan, Norman
dc.contributor.authorZhang, Hongbo
dc.contributor.authorPerino, Alessia
dc.contributor.authorLemos, Vera
dc.contributor.authorKim, Bohkyung
dc.contributor.authorPark, Young-Ki
dc.contributor.authorPiersigilli, Alessandra
dc.contributor.authorPham, Tho X
dc.contributor.authorYang, Yue
dc.contributor.authorSiah Ku, Chai
dc.contributor.authorKoo, Sung I
dc.contributor.authorFomitchova, Anna
dc.contributor.authorCantó, Carlos
dc.contributor.authorSchoonjans, Kristina
dc.contributor.authorSauve, Anthony A
dc.contributor.authorLee, Ji-Young
dc.contributor.authorAuwerx, Johan
dc.date.accessioned2024-10-24T16:24:35Z
dc.date.available2024-10-24T16:24:35Z
dc.date.issued2015-09-24
dc.description.abstractWith no approved pharmacological treatment, non-alcoholic fatty liver disease (NAFLD) is now the most common cause of chronic liver disease in western countries and its worldwide prevalence continues to increase along with the growing obesity epidemic. Here we show that a high-fat high-sucrose (HFHS) diet, eliciting chronic hepatosteatosis resembling human fatty liver, lowers hepatic NAD(+) levels driving reductions in hepatic mitochondrial content, function and ATP levels, in conjunction with robust increases in hepatic weight, lipid content and peroxidation in C57BL/6J mice. In an effort to assess the effect of NAD(+) repletion on the development of steatosis in mice, nicotinamide riboside (NR), a precursor for NAD(+) biosynthesis, was given to mice concomitant, as preventive strategy (NR-Prev), and as a therapeutic intervention (NR-Ther), to a HFHS diet. We demonstrate that NR prevents and reverts NAFLD by inducing a SIRT1- and SIRT3-dependent mitochondrial unfolded protein response (UPR(mt) ), triggering an adaptive mitohormetic pathway to increase hepatic β-oxidation and mitochondrial complex content and activity. The cell-autonomous beneficial component of NR treatment was revealed in liver-specific Sirt1 KO mice (Sirt1(hep-/-) ), while Apolipoprotein E-deficient (Apoe(-/-) ) mice challenged with a high-fat high-cholesterol diet (HFC), affirmed the use of NR in other independent models of NAFLD. CONCLUSION Our data warrant the future evaluation of NAD(+) boosting strategies to manage the development or progression of NAFLD. This article is protected by copyright. All rights reserved.
dc.description.numberOfPages15
dc.description.sponsorshipInstitut für Tierpathologie (ITPA)
dc.identifier.doi10.7892/boris.75642
dc.identifier.pmid26404765
dc.identifier.publisherDOI10.1002/hep.28245
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/137891
dc.language.isoen
dc.publisherWiley Interscience
dc.relation.ispartofHepatology
dc.relation.issn0270-9139
dc.relation.organizationInstitute of Animal Pathology
dc.relation.organizationDepartment of Infectious Diseases and Pathobiology (DIP)
dc.subjectmitonuclear protein imbalance nicotinamide riboside (NR)
dc.subjectnon-alcoholic fatty liver disease (NAFLD)
dc.subjectpoly(ADP-ribose) polymerases (PARPs) sirtuins
dc.subject.ddc600 - Technology::630 - Agriculture
dc.titleEliciting the mitochondrial unfolded protein response via NAD(+) repletion reverses fatty liver disease
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
oaire.citation.endPage1204
oaire.citation.issue4
oaire.citation.startPage1190
oaire.citation.volume63
oairecerif.author.affiliationInstitut für Tierpathologie (ITPA)
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.description.ispublishedpub
unibe.eprints.legacyId75642
unibe.journal.abbrevTitleHEPATOLOGY
unibe.refereedtrue
unibe.subtype.articlejournal

Files

Original bundle
Now showing 1 - 1 of 1
Name:
hep28245.pdf
Size:
1.43 MB
Format:
Adobe Portable Document Format
File Type:
text
License:
https://creativecommons.org/licenses/by-nc-nd/4.0
Content:
published

Collections